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ScienceDirectImmune escape strategies aimed to avoid T-cell recognition,
including the loss of tumor MHC class I expression, are
commonly found in malignant cells. Tumor immune escape has
proven to have a negative effect on the clinical outcome of
cancer immunotherapy, including treatment with antibodies
blocking immune checkpoint molecules. Hence, there is an
urgent need to develop novel approaches to overcome tumor
immune evasion. MHC class I antigen presentation is often
affected in human cancers and the capacity to induce
upregulation of MHC class I cell surface expression is a critical
step in the induction of tumor rejection. This review focuses on
characterization of rejection, escape, and dormant profiles of
tumors and its microenvironment with a special emphasis on
the tumor MHC class I expression. We also discuss possible
approaches to recover MHC class I expression on tumor cells
harboring reversible/‘soft’ or irreversible/‘hard’ genetic lesions.
Such MHC class I recovery approaches might well synergize
with complementary forms of immunotherapy.
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Introduction
Cancer immunotherapy in humans has historically used a
variety of products that boost T lymphocyte responses,
such as IL-2 and IFN-a in melanoma and renal cell
carcinoma and bacterial products as BCG in bladderCurrent Opinion in Immunology 2016, 39:44–51 cancer therapy [1–3]. More recently, antigenic tumor
peptides or dendritic cells loaded with shared peptides
have been introduced to the clinic [4,5]. These therapies
created great expectations among clinical oncologist be-
cause they could activate specific anti-tumor T-cell im-
munity. However, the observed tumor regressions were
below expectations [6]. The absence or downregulation
of tumor MHC class I (MHC-I) molecules could be one of
possible explanations for these disappointing results,
since MHC-I expression on cancer cells is required for
detection and destruction by T-cells [7,8]. MHC-I loss or
dowregulation is a major tumor escape mechanism from T
lymphocytes described in human tumors of different
origin [9–12]. The HLA evaluation in human tumor
tissues needs a complex approach since HLA class I
(HLA-I) heavy chains are highly polymorphic and
requires analysis of the expression of six HLA-I alleles
on tumor cell surface which differ among cancer patients
[13]. It is obvious that the information about tumor HLA
expression mostly comes from the analysis of progressing
tumors, which have already developed escape strategies.
In contrast, the tumor rejection profile is difficult to study
since such regressing lesions either disappear in a short
period of time or progress while acquiring the immunoe-
dited escape phenotype [14]. There are also evidences
that some tumor cells can survive in the host in a ‘dormant
state’ for long periods of time without being detected.
These dormant tumor cells ‘awake’ in immune-compro-
mised environments, especially when CD4+ and CD8+
lymphocytes are not present or their numbers are heavily
reduced [15,16].
The intimate interaction of MHC class I
expression by tumors and the T-cell immune
pressure
One of the major problems facing any type of cancer
treatment is the extensive heterogeneity of primary
tumors, which arises as a result of genetic and epigenetic
alterations at a clonal level [17,18]. In a mouse model of 3-
methyl-cholantrene-induced fibrosarcoma we observed
that primary tumor clone diversity is characterized by
different expression patterns of MHC-I genes and mole-
cules [19]. This explosion of diversity can be described as a
‘big bang’ because of the large variety of different tumor
cells with different genotypes and phenotypes, and be-
cause it can be detected few weeks after the injection of the
chemical carcinogen. Genetic alterations in any particular
marker creating this heterogeneity is probably a randomwww.sciencedirect.com
MHC-I recovery for cancer immunotherapy Garrido et al. 45process, but the interaction with the host immune system
determines the capacity of a given tumor cell clone to
survive and disseminate. Therefore, a process of ‘selec-
tion’, especially due to T-cell immune pressure on MHC-I
deficient tumor variants, might represent a natural process.
We and other groups have evidence that this strong selec-
tion process mediated by the interaction of MHC-I andFigure 1
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early stages of tumor development leading to either tumor
rejection or immune escape via immunoediting [19,20].
Tumors are predominantly MHC-I positive at early stages.
The specific antitumor CD8+T-cells attack is progressive-
ly killing MHC-I positive cells and selecting MHC nega-
tive ones (Figure 1). The MHC-I heterogeneity can be
observed in many tumors at these early stages. Finally, theeneity and Patterns of
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46 Tumour immunologyT cell immunoediting leaves tumors homogeneously defi-
cient or completely negative for MHC-I expression
[20,21]. A clinical example of T-cell mediated immuno-
selection of MHC-I negative tumor cells came from the
study of melanoma lesions derived from a single patient
during the course of cancer progression. A point mutation
present in the codon 67 of the beta 2-microglobulin gene in
HLA-I negative melanoma cells from the heterogeneous
primary tumor was found 10 months later in an uniformly
HLA-I-negative metastatic lesion, strongly suggesting an
active T-cell immunoselection of MHC-I negative mela-
noma cells [21].
In a mouse cancer model, a very clear example of T cell
mediated immunoselection came from the assessment of
H-2 expression in metastatic lung colonies obtained from
an H-2 negative tumor cell clone growing in immuno-
competent and in immunodeficient mice [22,23]. Lung
metastatic colonies growing in immunocompetent synge-
neic mice were H-2 negative. In contrast, colonies grow-
ing in immunodeficient mice lacking T-cells were H-2
positive. The mechanism responsible for the H-2 down-
regulation in this tumor clone was reversible (‘soft’) since
the expression of H-2 antigens could be recovered by
IFN-g [22,23]. We also observed that MHC-I positive
tumor clones are highly immunogenic, while MHC-I
negative variants have low immunogenicity. Neverthe-
less, when the number of locally injected tumor cells from
MHC-I positive clone is considerably large, they generate
local tumors and develop a high number of distant me-
tastases, because are able to overcome T-cell responses
and induce immunosuppression [22]. Importantly, MHC-
I positive lung metastases in this model could be
completely eradicated by immunotherapy [24]. In con-
trast, MHC-I negative tumor clones have none or low
metastatic capacity. They generate dormant micrometas-
tases with increased MHC-I expression, which are capa-
ble of inducing T-cell immune response (Figure 1) [15].
Tumor rejection profile
There are only few reports describing the MHC-I ex-
pression patterns in tumors undergoing rejection in
humans. This rejection can sometimes be induced using
different protocols of immunotherapy, including treat-
ment with IL-2, BCG, IFN-a, autologous tumor vaccine,
peptide vaccination or transfer of autologous anti-tumor
CD8+ T-cells, and is associated with the expression of
high levels of HLA-I molecules in tumor cells [20]. It is
difficult to obtain regressing malignant lesions, since
there are no clinical indications for surgical removal or
biopsy. In this situation, we rely only on the evaluation of
systemic CD8+ T-cell responses and intratumoral infil-
tration [25]. Nevertheless, we had an opportunity to
carefully analyze regressing and progressing subcutane-
ous melanoma lesions in two ‘mixed responder’ patients
after autologous vaccination [14,20]. We observed a mas-
sive intratumoral infiltration of CD4+ and CD8+Current Opinion in Immunology 2016, 39:44–51 lymphocytes (TILs) within the regressing melanoma
lesions with a positive correlation of high MHC-I levels.
In contrast, the lack of tumor HLA-I expression in
progressing lesions correlated with absence of TILs with
mostly peritumoral infiltration patterns [14,20]. These
two opposite patterns in distinct lesions of the same
patient reflect different phenotypes of tumor microenvi-
ronment, namely tumor rejection and tumor escape
(Figure 1). Tumor regression was also associated with
increased transcriptional upregulation of HLA and inter-
feron stimulation pathway genes pointing to an enhanced
antigen presentation capability of tumor cells [14]. This
histological and molecular signature of tumor rejection
mediated by CD8+ T-cells seems to be similar to that
found in allograft rejection and graft versus host disease
suggesting an existence of an immunological circuitry of
rejection [26].
High degree of tumor infiltration with T-cells is consid-
ered to be a good prognostic factor [27] and has been
included into a new tumor immunological grading system
called ‘immunoscore’ [28]. We have previously observed
in various types of cancers that the HLA-I negative
tumors lack TILs. In contrast, HLA-I positive tumors
are characterized by high degree of intratumoral infiltra-
tion with CD8+ T cells [14,20]. The status of intratumoral
infiltration, perhaps, reflects the stage of cancer immune
escape during natural cancer progression. At early stages
there are more HLA-positive tumor cells and many TILs,
while at more advanced stages tumor contains more
HLA-negative escape variants and T-cells are restrained
in the peritumoral area (Figure 1).
Tumor HLA-I expression patterns have been discussed at
the 12th International Histocompatibility Workshop (Paris,
France, June 9–12, 1996). Tumors sections were classified
as HLA-I negative (<25% tumor cells stained), heteroge-
neous (between 25% and 75% tumor cells labeled) and
positive (>75% tumor cells stained) [13,29]. It would be
interesting to determine whether the lack of HLA-I is the
cause of poor T-cell recruitment into the tumor or, the other
way around, the local infiltrating T cells mediate high
HLA-I expression by producing IFN-g. A recent report
indicated that the latter option could be valid, at least in
sarcomas [30]. In this context, the broadened melanoma-
reactive CD8+T cell responses reported after anti-CTLA-4
therapy in melanoma [31,32,33] could be associated with
the upregulation of MHC expression and could lead to the
presentation of a variety of previously hidden tumor spe-
cific peptides, which subsequently activate a pre-existing
T-cell pool. Similar events were previously reported in
clinical trials using peptide-based immunotherapy and
were defined as ‘epitope spreading’ [25,34].
Tumor escape profile
It is well established that tumor immune escape is asso-
ciated with MHC-I downregulation, as seen in differentwww.sciencedirect.com
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previous reports [8,10,12,35]. Tumors with this profile can
be derived from established progressed tumors after they
had escaped T-cell mediated immunosurveillance [11]. A
tumor derived from an HLA-I positive epithelium can
lose totally or partially the expression of class I molecules
[9]. The total percentage of various types of HLA-I loss,
including total loss, haplotype loss, or allelic loss, ranges
from 65 to 90%, depending on the type of cancer
[9,35,36].
Another evidence of tumor escape and the resistance to T
cell immunity caused by MHC-I down-regulation has
been corroborated by a cancer in a small mammal, the
Tasmanian Devil. A facial tumor in the Tasmanian Devil
silenced the genes for antigen presentation at the epige-
netic level and thereby created an infectious cancer that is
transmissible to histo-incompatible companions
[37,38,39]. This curious case of a transmissible tumor
clearly emphasizes the relevance of MHC loss for im-
mune escape of tumors. The clear impression in the field
is that most MHC-I defects in human cancers belong to
the category of ‘soft’-wired lesions [40,41–43]. Conse-
quently, this type of immuno-editing can be counteracted
by clever therapeutic targeting, such as activation of the
interferon signaling pathway in cancers or intervention
with HDAC inhibitors [44].
Tumor dormancy profile
Clinical and experimental evidence indicate that the
immune system can maintain cancer cells in a dormant
state [15,16]. Metastatic tumor cells can remain in a
state of equilibrium with the immune system for long
periods of time during which metastatic colonies do not
progress and the cellular immune response does not
reject the tumor. It resembles the symbiotic co-exis-
tence we see in different species when each partner
benefits from another in a particular ‘status quo’ of no
aggression. Despite clinical reports suggesting that im-
munosuppression is associated in humans with clinical
appearance of metastatic colonies [45], the profile of the
dormant microenvironment is not precisely known. We
have developed a mouse tumor model (GR9) in which
several metastatic tumor nodules were kept in a per-
manent state of immune-mediated dormancy in an
immunocompetent host [15]. Interestingly, when
the mice were depleted of CD8-T lymphocytes the
colonies started to growth resulting in overt metastases.
Moreover, the same tumor clone produced overt pul-
monary metastases in nude mice. Tumor cells capable of
generating these dormant metastatic colonies are very
exceptional; they were completely negative for MHC-I,
but the dormant micrometastases  recovered MHC-I
surface expression (Figure 1) [15]. These results
suggested that MHC-I surface expression and CD8+
T lymphocytes play an important role in immune-
mediated dormancy [46] (Figure 1).www.sciencedirect.com Antitumor strategies could be directed to harness the
immune response to maintain cancer cells in a permanent
dormant state or to favor a complete tumor rejection. In
the GR9 mouse tumor model, immunotherapy turned a
highly metastatic tumor clone into dormant micrometas-
tases ([24] and Garcia Lora et al., unpublished observa-
tions). Upregulating MHC-I expression on tumor cells by
cytokines, by increasing FHIT gene expression [47], by
blockade of the immune-checkpoint inhibitors, by sup-
pression of T regulatory cells or myeloid suppressor cells
could lead to activation of anti-tumor T lymphocyte
responses [44]. An attractive strategy for the restoration
of MHC-I expression is by epigenetic modifiers, like
inhibitors of DNA methyltransferase (DNMT) or histone
deacetylase (HDAC). In several recent papers, such reg-
ulation at the epigenetic level was shown to be able to
synergize with immunotherapy for the eradication of
mouse tumor models [48,49,50]. Interestingly, IFN-g-
induced restoration of ‘soft’ lesions of MHC-I, one of the
most powerful inducers of this gene, was shown to partly
mediate its effect by inducing demethylation of antigen-
processing machinery related genes, including the TAP
genes and LMP-2 [51].
How to deal with ‘hard’ lesions? Gene therapy
and alternative lymphocytes
Targeting the tumor escape phenotype is one of the major
tasks of the present and future cancer therapies [44]. In
the examples referred to above, the molecular mechanism
responsible for the HLA-I downregulation is reversible or
‘soft’ [40,52]. In contrast, when the genes of HLA or beta
2-microglobulin are corrupted due to mutations or dele-
tions resulting in loss of heterozygosity (LOH) at chro-
mosomes 6 or 15, the HLA-I loss is irreversible due to
these ‘hard’ lesions [53–55]. In this case, tumor cells
cannot recover the antigen presentation capacity and
the tumor microenvironment retains tumor escape phe-
notype favoring cancer progression. ‘Hard’ HLA-I aber-
rations in tumors (LOH in chromosomes 6 or 15 and beta
2-microglobulin mutations) are in the range of 30–40% of
human cancers [55,56]. In order to restore HLA-I expres-
sion in human tumors with ‘hard’ lesions we have made a
recombinant adenovirus carrying beta 2-microglobulin
gene and demonstrated a recovery of HLA-I expression
on tumor cells deficient in beta 2-microglobulin. This
HLA reconstitution also recovered tumor cell destruction
by peptide specific CD8+ T-cells in HLA-restricted man-
ner [57–59].
Natural killer (NK) cells provide a natural barrier against
MHC-I negative tumors and are, therefore, interesting
immune effectors to exploit in the treatment of immune-
escaped tumors with ‘hard’ lesions. However, there is no
clear evidence suggesting that NK cells selectively infil-
trate MHC-I negative tumor tissues. Tumor-infiltrating
NK cells might harbor an anergic phenotype in MHC-I
low tumors, in contrast to MHC-I-positive tumors [60].Current Opinion in Immunology 2016, 39:44–51
48 Tumour immunologyThis anergic state was reversed with IL-12/IL-18 treat-
ment and was even further enhanced by an improved
form of IL-2, leading to NK-dependent tumor control.
Another group showed that transfer of in vitro pre-acti-
vated NK cells, in combination with body irradiation, was
effective in eradication of tumors with ‘hard’ genetic
lesion in the MHC-I pathway [61]. Interestingly, addition
of HDAC inhibitors can increase the susceptibility of
cancer cells for NK cells by upregulation of the NKG2D-
activating ligand MICA [62,63]. In addition to upregula-
tion of its ligands, the NKG2D receptor was also upre-
gulated, which led to a further enhanced cytotoxicity of
tumor cells [62]. However, caution is needed, as tumor
cells treated with HDAC inhibitors might reduce their
levels of other activating ligands, as shown for B7-H6,
which stimulates NK cells via the NKp30 receptor [64].
Some years ago, our group identified a novel group of
CD8+ T cells which specifically recognize cells with low
MHC-I expression due to a defect in the peptide trans-
porter TAP [65,66]. These T cells recognize an alter-
native peptide repertoire on immunoescaped tumor cells.
We named these peptides TEIPP, for ‘T cell epitopes
associated with impaired peptide processing’ and they
emerge in the residual MHC-I molecules as a result of
alternative antigen processing pathways [67,68]. We
showed that the prototypic TEIPP epitope, derived from
the housekeeping protein Trh4, is processed by signal
peptide peptidase and is, therefore, processed indepen-
dently of TAP or the proteasome [69]. In a novel TCR
transgenic mouse model based on the Trh4-specific CD8+
T cell clone, we observed an efficient thymic selection of
these T cells, indicating that the TEIPP T cell repertoire
is not affected by central tolerance [70]. In addition, the
TEIPP T cells were effective in tumor control of the
TAP-deficient RMA-S tumor. We anticipate that this
CD8+ T cell subset can be exploited for treatment of
immune-escaped tumors.
Conclusions
We have defined the following three major tumor phe-
notypes relevant for tumor-host interactions and anti-
tumor immunity: rejection, escape and dormancy. We
highlighted the key role of tumor MHC expression that
influences the degree and composition the immune
cellular infiltration. This type of cellular immune re-
sponse markedly determines the prognosis and clinical
outcome in different types of malignancies. There is
accumulating evidence suggesting that the efficacy of
traditional (IL2, BCG, peptides, etc.) and newly devel-
oped immunotherapy (‘immune checkpoint’ blocking
antibodies) depends on the expression levels of MHC-
I on tumors cells [49]. ‘Soft’ MHC-I molecular lesions can
be recovered by a variety of interventions that modify
tumor microenvironment in such a way that Th1 type
cytokines are released. ‘Hard’ MHC molecular lesions
can only be corrected by transferring the appropriate wildCurrent Opinion in Immunology 2016, 39:44–51 type MHC-I or beta 2-microglobulin gene, or by the
application of natural killer cells and TEIPP-specific T
cells. Hence, identification of molecular aberrations re-
sponsible for altered tumor MHC-I expression, as well as
monitoring the evolution of this expression during the
course of treatment becomes essential for the success
of T-cell mediated cancer immunotherapy and for the
development of novel complementary approaches
for MHC-I upregulation. We are undoubtedly oversim-
plifying the enormous complexity of the tumor microen-
vironment but future findings of key molecules and/or
cells capable of overriding the immune escape routes
used by tumor cells will certainly help in inducing dura-
ble tumor rejection. Among them, MHC re-expression is
a major target for future studies.
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